The St. Louis-Cape Girardeau CCOP is a consortium of five hospitals serving parts of eastern Missouri and western Illinois. The mission of this organization is to provide access to clinical trials for community oncologists and their patients. St. John's Mercy Medical Center, the primary institution in the CCOP, is a tertiary care teaching hospital in St. Louis County. The other component hospitals are primarily located is smaller, rural communities with underserved patient populations. Providing access to state-of-the-art cancer treatment to these patients in their own community, and thus increasing involvement of these populations in clinical research, are important goals of the CCOP. One-thrid of all patients accrued to NCI treatment and preventiontrials are enrolled at CCOP sites. The program includes cancer treatment, prevention and control studies that benefit not only people with cancer but also people at high risk for cancer. It offers a variety of Phase II and III protocols including radiation therapy through RTOG, adjuvant treatment of breast and colorectal cancer through NSABP, and chemotherapy-based treatment of all major cancer types through SWOG. The repertoire of clinical trials is supplemented by using the CTSU menu as needed. Over the next five years approximately 80 patients per year will be enrolled in cancer treatment trials through the St. Louis-Cape Girardeau CCOP. SWOG, NSABP, and RTOG also offer cancer prevention and control studies which are a major focus of the CCOP. The St. Louis-Cape Girardeau CCOP was one of the top accruing sites for the STAR breast cancer prevention study and anticipates similar success with the upcoming STELLAR study. Approximately 60 cancer prevention and control credits are expected during each year of this grant period. By providing access to clinical trials in cancer treatment and prevention, the CCOP hopes to improve cancer care in the communities of western Illinois and eastern Missouri. When clinical trial participants are drawn from community hospitals and not just from universities, the study results are more applicable and relevant to the general population. The St. Louis-Cape Girardeau Community Clinical Oncology Program will do its part to achieve the NCI's goal to eliminate suffering and death due to cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA035128-28S1
Application #
8519725
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Program Officer
Kelaghan, Joseph
Project Start
1987-06-01
Project End
2013-05-31
Budget Start
2012-08-10
Budget End
2013-05-31
Support Year
28
Fiscal Year
2012
Total Cost
$421,379
Indirect Cost
$122,529
Name
St. John's Mercy Medical Center
Department
Type
DUNS #
071958003
City
Saint Louis
State
MO
Country
United States
Zip Code
63141
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-40
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Friedberg, Jonathan W; Unger, Joseph M; Burack, W Richard et al. (2014) R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. Br J Haematol 166:382-9
Coleman, Robert L; Moon, James; Sood, Anil K et al. (2014) Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer 50:1638-48
Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42
Deininger, Michael W; Kopecky, Kenneth J; Radich, Jerald P et al. (2014) Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol 164:223-32

Showing the most recent 10 out of 106 publications